Materials | Company Research



17March 2015

BUY **Unchanged**

Market Data: Mar.16 Closing Price (HK\$) 0.96 Price Target (HK\$) 1.50 11.814 HSCCI 4.403 52-week High/Low (HK\$) 1.16/0.70 Market Cap (US\$m) Market Cap (HK\$m) 4.365 Shares Outstanding (m) 4 517 Exchange Rate (Rmb-HK\$) 1.26 Price Performance Chart:

20%

Source: Bloomberg

Analyst

Rong Ye A0230512110001 AYZ033

Dimi Du A0230514070005 **BEE282**

Daniel Huang A0230513030001 BDO227

Contact

Hunter Du

(+86) 21 23297818×7241 duhm@swsresearch.com

Related Reports

"WEST CHINA CEMENT LTD (2233 HK): Turnaround time "Mar 4,2015

The company does not hold any equities or derivatives of the listed company mentioned in this report ("target"), but then we shall provide financial advisory services subject to the relevant laws and regulations. Any affiliates of the company may hold equities of the target, which may exceed 1 percent of issued shares subject to the relevant laws and regulations. The company may also provide investment banking services to the target. The Company fulfills its duty of disclosure within its sphere of knowledge. The clients may contact compliance@swsresearch.com for relevant

disclosure materials or log into www.swsresearch.com under disclosure column for further information. The clients shall have a comprehensive understanding of the disclosure and disclaimer upon the last page.

财报低于预期,但应展望未来

中国西部水泥(2233:HK)

Financial summary and valuation						
	2013	2014	2015E	2016E	2017E	
Revenue (Rmbm)	4,168	3,883	4,853	5,358	5,490	
YoY (%)	18.3	(6.8)	25.0	10.4	2.5	
Net income (Rmbm)	378	36	410	605	623	
YoY (%)	3.7	(90.5)	1,042.8	47.4	3.0	
EPS (Rmb)	0.08	0.01	0.09	0.13	0.14	
Diluted EPS (Rmb)	0.08	0.01	0.09	0.13	0.14	
ROE (%)	7.4	0.7	7.7	10.3	9.8	
Debt/asset (%)	0.1	0.1	0.1	0.1	0.1	
Dividend yield (%)	2.65	0.21	2.40	3.53	3.64	
PE (x)	9.1	96.7	8.5	5.7	5.6	
PB (x)	0.7	0.7	0.7	0.6	0.6	
EV/Ebitda (x)	5.4	7.2	5.1	3.9	3.4	

Note: Diluted EPS is calculated as if all outstanding convertible securities, such as convertible preferred shares, convertible debentures, stock options and warrants, were exercised.

令人失望的 2014 中国西部水泥(2233:HK 的 2014 年财报显示其净利润为人民币 35.9 百万元,每股净利润为 0.008 元(同比减少 90%)。剥离关于外汇损失,债务 赎回和损失相关的约1亿元人民币的一次性损失,其净利润约为人民币160百万元, 依然大幅度低于彭博和我们的预期。

2H14 较低的吨毛利和高于预期的单位费用与税率 2H14 的销量为 8.6 百万吨,环比 增长3%,同比减少9%。公司2H14的吨售价为人民币218元,,低于上半年的人 民币 239 元每吨约 21 元,从而导致了 2H14 的吨毛利为人民币 25 元(我们此前预 计 27 元, 1H14 为 46 元), 从而导致 14 年全年吨毛利为人民币 35 元。由于一次 性的损失,单位其他收入为-2元每吨,比1H14的8元每吨减少了10元。较低的利 息资本化率导致了较高的每吨利息费用为人民币 15 元,环比 1H14 的每吨 11 元增 加 4 元。2H14 的单位税费为每吨 5 元,高于我们预期的每吨 2 元。较低的吨毛利, 和其他收入的净损失,再加上较高的财务成本一起导致了 2H14 的每吨净损失为人民 币 14 元,拉低全年的每吨净收益至人民币 2.1 元

负债率和固定资本支出保持稳定公司净负债从 1H14 的人民币 33.1 亿略增至 4Q14 的 34.1 亿元,净负债率稳定在 68% (1H14 为 65%) ,与 2H13 的 67%相当。西部 水泥 2014 年全年固定资本支出为人民币 7.2 亿元,比 13 年的 7.4 亿元略低 2%

最坏的时期已过目前安徽海螺(914:HK)的陕西中部水泥厂海螺礼泉的高标水泥售 价为人民币 245 元每吨,比 14 年十月中旬的底部价格人民币 180 元每吨高了 65 元。 尤其海螺礼泉处于当地市场成本曲线最低端,可以当作陕西境内的水泥价格风向 标。所以我们认为这是陕西省水泥价格复苏的的早期信号。再加上 15-16 年陕西身 的供求关系改善,我们认为最坏的时刻已经过去,西部水泥的基本面在改善。

维持买入评级西部水泥目前正交易在人民币 257 元每吨的 15 年企业吨价值/产能, 低于行业平均置换成本的人民币 400 元每吨。股价如果因为业绩下跌将是很好的买 入机会。我们维持港币 1.5 元的目标价不变(对应 15 年吨企业价值/产能为人民币 310 元)以显示公司基本面反转的潜力和陕西当地的价格上涨趋势。基于 56%的上 行空间,我们重申买入评级。



Depressed 2014 results. West China Cement (WCC) announced FY14 results with net profit at Rmb35.9m (-90% YoY) and EPS at Rmb 0.008 (-90% YoY). Excluding one-off losses of c.Rmb100m, as the result of Forex losses, bond redemption and impairment, net profit would reach Rmb160m, significantly lower than both Bloomberg consensus and our estimates.

Lower margin, but higher-than-expected expenses and tax rate. In 2H14, sales volume was 8.6m tonnes (+3% HoH and -9% YoY). The company's average selling price (ASP) fell Rmb21/t from Rmb239/t in 1H14 to Rmb218/t in 2H14, resulting in a unit margin drop from Rmb46/t in 1H14 to Rmb25/t in 2H14 (vs our forecast of Rmb27/t) and Rmb35/t for full-year 2014. Due to one-off losses, unit other income declined Rmb10/t from Rmb8/t in 1H14 to Rmb-2/t in 2H14. Lower interest capitalisation rate led to higher unit interest expenses from Rmb11/t in 1H14 to Rmb15/t in 2H14. Unit tax reached Rmb5/t in 2H14, higher than our expectation of Rmb2/t. The combination of lower unit margin, negative other income and higher financing costs will result in a unit net loss of Rmb14/t in 2H14, resulting in declining full-year 2014 unit net profit of Rmb2.1/t.

Net gearing and Capex stablise. Net debt rose to Rmb331mn in 4Q14, leading to stable net gearing of 68% (65% in 1H14 and 67% in 2H13). WCC's total Capex was Rmb720mn in 2014 (-2% vs Rmb740mn in 2013).

Worst has passed. Currently, Anhui Conch Cement's (914:HK) central Shaanxi Province-based plant, Conch Liquan, is selling P.O.42.5 cement at Rmb245/t, Rmb65/t higher vs the bottom of Rmb180/t in mid-October 2014. We interpret this as an early signal of a price rebound in Shaanxi as this plant operates at the low end of the regional cost curve and can be considered the price setter in the region. Given other signals of improving supply demand dynamics in 2015-16 in the region, we believe the worst is over and WCC's prospects are improving.

Maintain BUY. WCC is trading at 15E EV/capacity of Rmb257/t, 36% below the industry replacement cost of Rmb400/t. Investors should look beyond the results. We maintain our target price at HK\$1.50 (implying a 15E EV/capacity of Rmb310/t) reflecting the turnaround potential and positive price trend in Shaanxi. With 56% upside, we maintain our BUY recommendation.



APPENDIX

Fig 1: WCC's unit data forecasts

Rmb/t	1H 14	2H14	2014	15E	16E	17E
Volume, 000	8,360	8,640	17,000	20,475	21,870	22,410
ASP	239	218	228	237	245	245
ACP	-193	-194	-193	-195	-195	-195
Gross profit	46	25	35	42	50	50
Other Income	8	-2	3	10	10	10
SG&A	-18	-17	-17	-17	-17	-17
Finance cost	-11	-15	-13	-9	-8	-8
Expenses	-29	-32	-31	-27	-25	-25
Earnings before tax	25	-8.9	7.9	25	35	35
Tax (%)	-23%	60%	-71%	-20%	-20%	-20%
Tax/t	-6	-5	-6	5	7	7
Minorities	0.26	0.16	0.21	0.30	0.30	0.30
Net profit/t	19.2	-14.4	2.1	20	28	28
Net profittotal (Rmbm)	160	-124	36	410	605	623

Source: Company, SWS Research


Fig 2: WCC 2H14 results VS. SWS estimates

Rmb/t	1H13	2H13	1H14	2H14	2H14SWS E	% Diff
Volume, 000	8100	9500	8360	8640	9160	-5.7%
ASP	243	232	239	218	217	0.6%
ACP	-200	-191	-193	-194	-190	1.9%
Gross profit	43	40	46	25	27	-8.7%
Other Income	15	12	8	-2	8	-122.9%
SG&A	-18	-14	-18	-17	-18	-3.3%
Finance cost	-13	11	-11	-15	-23	-33.1%
Expenses	-32	-2	-29	-32	-40	-20.2%
Earnings before tax	27	27	25	-9	-5	63.5%
Tax (%)	-21%	-18%	-23%	60%	35%	70.7%
Tax/t	-6	-5	-6	-5	-2	179.1%
Minorities	0.25	0.73	0.26	0.16	-0.01	-1703.0%
Net profit/t	21	22	19	-14	-7	96.2%
Net profit total (Rmbm)	168	205	160	-124	-67	85.0%

Source: Company, SWS Research




Fig 3: Price change in 2014-15 in Conch Liquan cement plantin central Shaanxi



Source:SCI 99, SWS Research

Fig 4: WCC EV/t band



Source: Bloomberg, SWS Research



Table 1: Consolidated Income Statement

Rmbm	2013	2014	2015E	2016E	2017E
Revenue	4,168	3,883	4,853	5,358	5,490
Cost of Sales	(3,439)	(3,285)	(3,993)	(4,265)	(4,370)
Gross Profit	729	598	860	1,094	1,121
b Other Income	237	53	205	219	224
Distribution expenses	(35)	(36)	(61)	(66)	(67)
e Administrative expenses	(244)	(258)	(307)	(328)	(336)
EBITDA	1,259	941	1,280	1,495	1,508
2 EBIT	687	357	696	919	941
Finance Costs	(212)	(222)	(190)	(170)	(170)
O Profit before tax	475	135	521	764	787
Income tax expense	(93)	(96)	(104)	(153)	(157)
S Minority interests	4	4	6	7	7
O Profit for the year	378	36	410	605	623

Source: Company, SWS Research

d

ated Cash Flow Statement

Rmbm	2013	2014	2015E	2016E	2017E
Profit before taxation	459	135	521	764	787
Plus: Depr. and amortisation	464	584	584	577	566
Finance cost	140	222	190	170	170
Losses from investments	(5)	0	0	0	0
Change in working capital	392	272	(203)	(22)	17
Others	(73)	(96)	(104)	(153)	(157)
CF from operating activities	1,374	1,117	987	1,336	1,383
CAPEX	(563)	(466)	(485)	(375)	(384)
Other CF from investing activities	(838)	0	0	0	0
CF from investing activities	(1,401)	(466)	(485)	(375)	(384)
Equity financing	0	0	0	0	0
Net change in liabilities	259	(0)	0	0	0
Dividend and interest paid	(344)	(229)	(272)	(291)	(295)
Other CF from financing activities	0	96	(309)	4	(40)
CF from financing activities	(136)	(134)	(581)	(287)	(335)
Net cash flow	(163)	518	(79)	674	665
FCFF	887	651	488	945	983
FCFE	1,006	429	298	775	813

Source: Company, SWS Research



Table 3: Consolidated Balance Sheet

Rmbm	2013	2014	2015E	2016E	2017E
Current Assets	1,891	1,857	2,437	3,234	3,937
Bank balances and cash	507	496	808	1,481	2,146
Trade and other receivables	737	601	751	829	850
Inventories	531	548	666	712	729
Long-term investment	29	39	0	0	50
PP&E	8,004	8,071	7,995	7,811	7,641
Intangible and other assets	915	1,052	948	926	955
Total Assets	10,694	10,768	11,168	11,760	12,320
Current Liabilities	2,294	2,362	2,427	2,528	2,584
Borrowings	709	745	745	745	745
Trade and other payables	1,444	1,598	1,663	1,764	1,820
Other current liabilities	3,420	3,326	3,326	3,326	3,326
Long-term liabilities	6	83	83	83	83
Total Liabilities	5,579	5,752	5,817	5,918	5,974
Minority Interests	41	46	52	58	65
Shareholder Equity	5,044	4,971	5,300	5,783	6,282
Share Capital	125	125	125	125	125
Reserves	145	0	0	0	0
Equity attributable	2,638	4,847	5,175	5,659	6,157
Total Liabilities and equity	10,665	10,768	11,168	11,760	12,320

Source: Company,SWS Research

Table 4: Key Financial Ratios

	2013	2014	2015E	2016E	2017E
Ratios per share (Rmb)					
Earnings per share	0.08	0.01	0.09	0.13	0.14
Operating CF per share	0.30	0.25	0.22	0.29	0.31
Dividend per share	0.02	0.00	0.02	0.03	0.03
Net assets per share	1.11	1.10	1.17	1.28	1.39
Key Operating Ratios(%)					
ROIC	7.09	4.08	7.34	9.50	9.92
ROE	7.44	0.72	7.67	10.35	9.81
Gross profit margin	17.50	15.40	17.72	20.41	20.41
EBITDA Margin	30.21	24.23	26.38	27.90	27.46
EBIT Margin	16.49	9.20	14.35	17.14	17.14
Growth rate of Revenue(YoY)	18.27	(6.83)	24.96	10.42	2.47
Growth rate of Profit(YoY)	3.68	(90.51)	1,042.76	47.35	3.02
Debt-to-asset ratio	0.07	0.08	0.07	0.07	0.07
Turnover rate of net assets	0.83	0.78	0.92	0.93	0.87
Turnover rate of total assets	0.39	0.36	0.43	0.46	0.45
Effective tax rate (%)	19.54	70.76	20.00	20.00	20.00
Dividend yield (%)	2.65	0.21	2.40	3.53	3.64
Valuation Ratios (X)					
P/E	9.09	96.69	8.46	5.74	5.57
P/B	0.68	0.70	0.66	0.60	0.55
EV/Sales	1.64	1.75	1.34	1.08	0.94
EV/EBITDA	5.43	7.22	5.07	3.89	3.41

Source: Company, SWS Research

Information Disclosure:

The views expressed in this report accurately reflect the personal views of the analyst. The analyst declares that neither he/she nor his/her associate serves as an officer of nor has any financial interests in relation to the listed corporation reviewed by the analyst. None of the listed corporations reviewed or any third party has provided or agreed to provide any compensation or other benefits in connection with this report to any of the analyst, the Company or the group company(ies). A group company(ies) of the Company confirm that they, whether individually or as a group (i) are not involved in any market making activities for any of the listed corporation reviewed; or (ii) do not have any individual employed by or associated with any group company(ies) of the Company serving as an officer of any of the listed corporation reviewed; or (iii) do not have any financial interest in relation to the listed corporation reviewed or (iv) do not, presently or within the last 12 months, have any investment banking relationship with the listed corporation reviewed.

Undertakings of the Analyst

I (We) am (are) conferred the Professional Quality of Securities Investment Consulting Industry by the Securities Association of China and have registered as the Securities Analyst. I hereby issue this report independently and objectively with due diligence, professional and prudent research methods and only legitimate information is used in this report. I am also responsible for the content and opinions of this report. I have never been, am not, and will not be compensated directly or indirectly in any form for the specific recommendations or opinions herein.

Disclosure with respect to the Company

The company is a subsidiary of ShenwanHongyuan Securities. The company is a qualified securities investment consulting institute approved by China Securities Regulatory Commission with the code number ZX0065.

Releasing securities research reports is the basic form of the securities investment consulting services. The company may analyze the values or market trends of securities and related products or other relevant affecting factors, provide investment analysis advice on securities valuation/ investment rating, etc. by issuing securities research reports solely to its clients.

The Company fulfills its duty of disclosure within its sphere of knowledge. The clients may contact compliance@swsresearch.com for the relevant disclosure materials or log into www.swsresearch.com for the analysts' qualifications, the arrangement of the quiet period and the affiliates' shareholdings.

Introduction of Share Investment Rating

Security Investment Rating:

When measuring the difference between the markup of the security and that of the market's benchmark within six months after the release of this report, we define the terms as follows:

Trading BUY: Share price performance is expected to generate more than 20% upside over a 6-month period.

BUY: Share price performance is expected to generate more than 20% upside over a 12-month period.

Outperform: Share price performance is expected to generate between 10-20% upside over a 12-month period.

 $Hold: Share \ price \ performance \ is \ expected \ to \ generate \ between \ 10\% \ downside \ to \ 10\% \ upside \ over \ a \ 12-month \ period.$

Underperform: Share price performance is expected to generate between 10-20% downside over a 12-month period.

SELL: Share price performance is expected to generate more than 20% downside over a 12-month period.

Industry Investment Rating:

When measuring the difference between the markup of the industry index and that of the market's benchmark within six months after the release of the report, we define the terms as follows:

Overweight: Industry performs better than that of the whole market;

Equal weight: Industry performs about the same as that of the whole market;

Underweight: Industry performs worse than that of the whole market.

We would like to remind you that different security research institutions adopt different rating terminologies and rating standards. We adopt the relative rating method to recommend the relative weightings of investment. The clients' decisions to buy or sell securities shall be based on their actual situation, such as their portfolio structures and other necessary factors. The clients shall read through the whole report so as to obtain the complete opinions and information and shall not rely solely on the investment ratings to reach a conclusion. The Company employs its own industry classification system. The industry classification is available at our sales personnel if you are interested.

HSCEI is the benchmark employed in this report.

Disclaimer:

This report is to be used solely by the clients of SWS Research Co., Ltd. (subsidiary of ShenwanHongyuan Securities, hereinafter referred to as the "Company"). The Company will not deem any other person as its client notwithstanding his receipt of this report.

This report is based on public information, however, the authenticity, accuracy or completeness of such information is not warranted by the Company. The materials, tools, opinions and speculations contained herein are for the clients' reference only, and are not to be regarded or deemed as an invitation for the sale or purchase of any security or other investment instruments.

The clients understand that the text message reminder and telephone recommendation are no more than a brief communication of the research opinions, which are subject to the complete report released on the Company's website (http://www.swsresearch.com). The clients may ask for follow-up explanations if they so wish.

The materials, opinions and estimates contained herein only reflect the judgment of the Company on the day this report is released. The prices, values and investment returns of the securities or investment instruments referred to herein may fluctuate. At different periods, the Company may release reports which are inconsistent with the materials, opinions and estimates contained herein.

Save and except as otherwise stipulated in this report, the contactor upon the first page of the report only acts as the liaison who shall not provide any consulting services.

The clients shall consider the Company's possible conflict of interests which may affect the objectivity of this report, and shall not base their investment decisions solely on this report. The clients should make investment decisions independently and solely at your own risk. Please be reminded that in any event, the company will not share gains or losses of any securities investment with the clients. Whether written or oral, any commitment to share gains or losses of securities investment is invalid. The investment and services referred to herein may not be suitable for certain clients and shall not constitute personal advice for individual clients. The Company does not ensure that this report fully takes into consideration of the particular investment objectives, financial situations or needs of individual clients. The Company strongly suggests the clients to consider themselves whether the opinions or suggestions herein are suitable for the clients' particular situations; and to consult an independent investment consultant if necessary.

Under no circumstances shall the information contained herein or the opinions expressed herein forms an investment recommendation to anyone. Under no circumstances shall the Company be held responsible for any loss caused by the use of any contents herein by anyone. Please be particularly cautious to the risks and exposures of the market via investment.

Independent investment consultant should be consulted before any investment decision is rendered based on this report or at any request of explanation for this report where the receiver of this report is not a client of the Company.

The Company possesses all copyrights of this report which shall be treated as non-public information. The Company reserves all rights related to this report. Unless otherwise indicated in writing, all the copyrights of all the materials herein belong to the Company. In the absence of any prior authorization by the Company in writing, no part of this report shall be copied, photocopied, replicated or redistributed to any other person in any form by any means, or be used in any other ways which will infringe upon the copyrights of the Company. All the trademarks, service marks and marks used herein are trademarks, service marks or marks of the Company, and no one shall have the right to use them at any circumstances without the prior consent of the Company.

This report may be translated into different languages. The Company does not warrant that the translations are free from errors or discrepancies.

This report is for distribution in Hong Kong only to persons who fall within the definition of professional investors whether under the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong) (the "SFO") or the Securities and Futures (Professional Investor) Rules (Chapter 571D of the laws of the Hong Kong under the SFO).

This report is for distribution in the United Kingdom only to persons who (i) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) order 2001 (as amended) (the "Order") or (ii) are persons falling within Article 49(2)(a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc") of the Order (All such persons together being referred to as "Relevant Persons"). This document is directed only at Relevant Persons. Other Persons who are not Relevant Persons must not act or rely upon this document or any of its contents.

Disclaimer

This report was prepared, approved, published and distributed by the SWS Research Co., Ltd (subsidiary of ShenwanHongyuan Securities) located outside of the United States (a "non-US Group Company"). This report is distributed in the U.S. by Enclave Capital LLC, a U.S. registered broker dealer, on behalf of SWS Research Co., Ltd only to major U.S. institutional investors (as defined in Rule 15a-6 under the U.S. Securities Exchange Act of 1934 (the "Exchange Act")) pursuant to the exemption in Rule 15a-6 and any transaction effected by a U.S. customer in the securities described in this report must be effected through Enclave Capital LLC (19 West 44th Street, suite 1700, New York, NY 10036).

Neither the report nor any analyst who prepared or approved the report is subject to U.S. legal requirements or the Financial Industry Regulatory Authority, Inc. ("FINRA") or other regulatory requirements pertaining to research reports or research analysts. No non-US Group Company is registered as a broker-dealer under the Exchange Act or is a member of the Financial Industry Regulatory Authority, Inc. or any other U.S. self-regulatory organization. The information has been compiled or arrived from sources believed to be reliable and in good faith, but no representation or warranty, express or implied is made as to their accuracy, completeness or correctness. SWS Research Co., Ltd has not verified the factual accuracy, assumptions, calculations or completeness of the information. Accordingly, SWS Research Co., Ltd. (subsidiary of ShenwanHongyuan Securities) accepts no liability whatsoever for any direct or consequential loss or damage arising from (i) the use of this communication (ii) reliance of any information contained herein, (iii) any error, omission or inaccuracy in any such Information or (iv) any action resulting there from. SWS Research Co., Ltd. (subsidiary of ShenwanHongyuan Securities) provides the information for the purpose of the intended recipient's analysis and review. Accordingly you are advised to verify the factual accuracy, assumptions, calculations or completeness of the information.

Analyst Certification

Each of the analysts identified in this report certifies, with respect to the companies or securities that the individual analyses, that (1) the views expressed in this report reflect his or her personal views about all of the subject companies and securities and (2) no part of his or her compensation was, is or will be directly or indirectly dependent on the specific recommendations or views expressed in this report.

Important US Regulatory Disclosures on Subject Companies

This material was produced by SWS Research Co., Ltd. (subsidiary of ShenwanHongyuan Securities) solely for information purposes and for the use of the recipient. It is not to be reproduced under any circumstances and is not to be copied or made available to any person other than the recipient. It is distributed in the United States of America by Enclave Capital LLC and elsewhere in the world by SWS Research Co., Ltd. (subsidiary of ShenwanHongyuan Securities) or an authorized affiliate of SWS Research Co., Ltd. (subsidiary of ShenwanHongyuan Securities). This document does not constitute an offer of, or an invitation by or on behalf of SWS Research Co., Ltd. (subsidiary of ShenwanHongyuan Securities) or its affiliates or any other company to any person, to buy or sell any security. The information contained herein has been obtained from published information and other sources, which SWS Research Co., Ltd. (subsidiary of ShenwanHongyuan Securities) or its Affiliates consider to be reliable. None of SWS Research Co., Ltd. (subsidiary of ShenwanHongyuan Securities) accepts any liability or responsibility whatsoever for the accuracy or completeness of any such information. All estimates, expressions of opinion and other subjective judgments contained herein are made as of the date of this document. Emerging securities markets may be subject to risks significantly higher than more established markets. In particular, the political and economic environment, company practices and market prices and volumes may be subject to significant variations. The ability to assess such risks may also be limited due to significantly lower information quantity and quality. By accepting this document, you agree to be bound by all the foregoing provisions.

- 1. SWS Research Co., Ltd. (subsidiary of ShenwanHongyuan Securities) or its Affiliates have not recently been the beneficial owners of 1% or more of the securities mentioned in this report.
- 2. SWS Research Co., Ltd. (subsidiary of ShenwanHongyuan Securities) or its Affiliates have not managed or co-managed a public offering of the securities mentioned in the report in the past 12 months.
- 3. SWS Research Co., Ltd. (subsidiary of ShenwanHongyuan Securities) or its Affiliates have not received compensation for investment banking services from the issuer of these securities in the past 12 months and do not expect to receive compensation for investment banking services from the issuer of these securities within the next three months.
- 4. However, one or more person of SWS Research Co., Ltd. (subsidiary of ShenwanHongyuan Securities) or its affiliates may, from time to time, have a long or short position in any of the securities mentioned herein and may buy or sell those securities or options thereon either on their own account or on behalf of their clients.
- 5. As of the publication of this report Enclave Capital LLC, does not make a market in the subject securities.
- 6. SWS Research Co., Ltd. (subsidiary of ShenwanHongyuan Securities) or its Affiliates may, to the extent permitted by law, act upon or use the above material or the conclusions stated above or the research or analysis on which they are based before the material is published to recipients and from time to time provide investment banking, investment management or other services for or solicit to seek to obtain investment banking, or other securities business from, any entity referred to in this report

Distribution in Singapore

If distributed in Singapore, this report is meant only for Accredited Investors and Institutional Investors as defined under Section 4A of the Securities and Futures Act of Singapore. If you are not an Accredited Investor or an Institutional Investor, you shall ignore the report and its contents. The Singapore recipients of the report are to contact the Singapore office of ShenyinWanguo Singapore Private Limited at 65-6323-5208, or 65-6323-5209 in respect of any matters arising from, or in connection with, the report.